English
Regional settings| Spread | 1.68 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 134.21 |
| Open | 132.81 |
| 1-Year Change | -29.57% |
| Day's Range | 132.81 - 134.32 |
Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive technologies and hospital automation solutions. Its patient monitoring solution that incorporates a monitor or circuit board, single-patient use or reusable sensors, software and cables. The Company’s main products include Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings include noninvasive monitoring of blood constituents with an optical signature, optical regional oximetry monitoring, electrical brain function monitoring, acoustic respiration monitoring, exhaled gas monitoring, nasal high flow ventilation, minimally invasive neuromodulation technology for pain. It sells its products hospitals, emergency medical service (EMS) providers, home care providers, long-term care facilities, physician offices, veterinarians and consumers through direct sales force, distributors and original equipment manufacturers (OEM) partners.
BRIEF: For the fiscal year ended 01 January 2022, Masimo Corporation revenues increased 8% to $1.24B. Net income decreased 4% to $229.6M. Revenues reflect United States segment increase of 8% to $822.4M, Asia and Australia segment increase of 19% to $123.6M. Net income was offset by Selling, General & Admin Exp increase of 16% to $355M (expense), Research and Development Expense - Balan increase of 15% to $124.8M (expense).
Common Stock $.001 Par, 4/11, 100M auth., 59,736,034 issd., less 156,240 shs. in Treas. @ $1.2M. Insiders own 9.23%. IPO 08/08/2007, 11.9MShares @ $17per share by PiperJaffray & Co and Deutsche Bank Securities Inc. 5/07, 3-for-1 forward stock split.
